Annual report 2016 - 2017
During the year, we celebrated 35 years of CRCHUS health discoveries. Also, the Fonds de recherche du Québec – Santé (FRQS) – funded operating grant of the CRCHUS was renewed this year, for which we were awarded a rating of «excellent».
These facts reflect the dynamism of CRCHUS researchers. We will continue deploying efforts to maintain and increase this level of efficiency.
Creation of the Strategy for Patient-Oriented Research: CRCHUS joins the Network!
Two Sherbrooke teams, led by Dr. André Carpentier and Louis Gendron, will receive a five-year investment of $50 million from the Canadian Institutes of Health Research and several partners for the creation of pan-Canadian research networks in the fight against diabetes and its complications and in the fight against chronic pain.
Patients and their families together with the research teams will develop research projects that focus on their concerns and needs.
Oral Vancomycin to Reduce Relapses of Clostridium difficile Infections
Alex Carignan discovered that, when oral vancomycin is administered simultaneously with an antibiotic nontargeted for C. difficile (such as an antibiotic for pneumonia or urinary infection), it effectively prevents recurrences of C. difficile infection in patients that have had at least one relapse in the past. The research team published an article on the subject in the renowned American Journal of Gastroenterology, which belongs to the Nature group. In addition to bringing about a major change to medical practice, this study consolidates the CRCHUS’ status as a North American leader in the epidemiology and treatment of C. difficile infections.
See also CIUSSS de l'Estrie - CHUS (to come) and Fondation du CHUS Annual Report (french).
* Report in French